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Vaccination is expected to make a major contribution to the goal of eliminating tuberculosis 
worldwide by 2050. But developing a new effective vaccine will require innovation in 
scientific research, a proactive approach to clinical trials of new vaccine candidates, and 
application of vaccines as part of an integrated approach to disease control.After decades of neglect, the 
immense public health impact of 
tuberculosis (TB) is now widely rec-
ognized. In 2004 alone, around 9 mil-
lion people developed active TB, with 
up to 2 million deaths attributable to 
the disease (WHO, 2006). Strategies 
to combat TB—announced at the 
World Economic Forum in Davos, 
Switzerland last month—are set out 
in The Global Plan to Stop TB (Stop 
TB Partnership and WHO, 2006). 
This plan addresses the UN Millen-
nium Development Goal of halving 
TB prevalence and death rates by 
the year 2015, that is, reducing the 
annual death toll from TB to less than 
1 million worldwide. This would be a 
big step toward the target of elimi-
nating TB worldwide by 2050 (set at 
one case per million population).
The current strategy for TB con-
trol is based on reducing the spread 
of infection through effective treat-
ment of individuals with active dis-
ease using drug combinations that 
include rifampicin and isoniazid. 
However, there are many problems 
with this approach, including the 
identification of TB patients living in 
conditions of poverty with little or no 
access to basic health services, the 
dramatic increase in susceptibility to 
TB of individuals who are coinfected 
with HIV, the emergence of strains 
of Mycobacterium tuberculosis that 
are resistant to front-line drugs, and 
the logistics of delivering a treatment 
that requires administration of mul-
tiple drugs over periods of 6 months or more. The Global Plan to Stop 
TB (Stop TB Partnership and WHO, 
2006) addresses each of these issues 
in a 50 billion dollar program that will 
treat 50 million patients and save 14 
million lives over the next 10 years. It 
is anticipated that the 2015 goals will 
be reached through optimized use 
of existing tools in combination with 
improvements in diagnostics and 
drugs, but vaccination is a critical 
component in the battle to control 
TB. The current vaccine—BCG (bac-
ille Calmette-Guérin)—is widely used 
in many parts of the world (although 
not in the United States) to protect 
against severe childhood forms 
of TB but is unreliable against the 
highly infectious pulmonary form of 
TB characteristically found in adults. 
There is a pressing need for new and 
better vaccines to fight TB.
Benefits of prevention over cure 
are self-evident, and vaccination 
has long been recognized as an 
optimal strategy to control TB. At 
first glance, prospects seem very 
attractive. Aerosols from the lungs 
of untreated TB patients provide a 
very effective means of spreading 
M. tuberculosis, resulting in annual 
rates of infection (detected by mea-
suring antigen-specific T cells) in the 
range of 0.5%–2.0% in TB endemic 
communities (B. Bourdin Trunz, 
P.E.M. Fine, and C.D., unpublished 
data). The estimate that one-third 
of the global population is infected 
with M. tuberculosis is commonly 
used to emphasize the huge over-Cell 124, Feall burden of TB (Dye et al., 1999). 
For the vast majority, induction of an 
immune response is the only detect-
able sign of infection. As a rule of 
thumb, around 5%–10% of infected 
individuals will develop active TB; 
half within the first few years after 
infection and half in later life as a 
result of reinfection or reactivation 
of an original infection. This risk is 
increased by an order of magnitude 
in individuals co-infected with HIV. 
Of the remaining 90% of healthy 
infected individuals, autopsy results 
show that a significant proportion 
continue to harbor viable bacte-
ria in the form of a latent infection 
(Stewart et al., 2003). From a vac-
cine standpoint, the key lesson is 
that the natural immune response 
already protects 90% of the popula-
tion from clinical disease. The ques-
tion is whether a modest increase 
in this immune response would 
increase protection to 100%.
Interferon-γ and the Natural 
Immune Response
The simplest way to assist the natu-
ral immune response is to prime it in 
advance of exposure to the patho-
gen. This was the strategy underlying 
development of an attenuated strain 
of Mycobacterium bovis by labora-
tory passage in the early decades 
of the twentieth century, generating 
BCG, one of the world’s most widely 
used vaccines. BCG performs as 
expected in a wide range of animal 
models by establishing a population bruary 24, 2006 ©2006 Elsevier Inc. 683
of primed T cells that respond more 
rapidly to subsequent challenge with 
virulent M. tuberculosis. Vaccination 
restricts the early phase of bacte-
rial growth and prolongs survival. 
Consistent with this, neonatal BCG 
vaccination in humans reduces the 
childhood incidence of severe forms 
of disseminated disease. According 
to recent estimates, the 100 million 
BCG vaccinations given to infants in 
2002 will have prevented 30,000 TB 
meningitis cases in children during 
their first 5 years of life, and about 
11,000 cases of disseminated or mili-
ary TB (B. Bourdin Trunz, P.E.M. Fine, 
and C.D., unpublished data).
However, BCG is less effective 
against the major infectious form 
of pulmonary TB. BCG vaccina-
tion of schoolchildren in the United 
Kingdom reduced the incidence of 
TB over the next 15 years by more 
than 70%. In contrast, no protec-
tion was observed following BCG 
vaccination in south India. The vari-
able effects of BCG in different loca-
tions may be associated with differ-
ing levels of background immunity 
induced by exposure to mycobacte-
ria in the environment. Where BCG 
does work, the protective effect has 
been shown to last for as long as 60 
years (Aronson et al., 2004). Also 
encouraging is a recent study that 
used measurement of responses to 
antigens that are absent from the 
vaccine strain (ESAT6/CFP10, see 
below) to demonstrate that BCG 
vaccination is able to arrest infec-
tion at an early stage, without the 
induction of M. tuberculosis-spe-
cific T cells (Soysal et al., 2005). 
However, the global TB epidemic 
is clearly thriving in spite of wide-
spread BCG vaccination. The partial 
protection that has been observed 
in clinical trials, together with the 
failure to identify alternative candi-
dates that substantially outperform 
BCG in experimental models, has 
encouraged a search for new vac-
cines that can be used in combina-
tion with BCG.
The dominant immunological con-
sequence of infection with M. tuber-
culosis or vaccination with BCG is 
priming of Th1-oriented CD4+ T cells 684 Cell 124, February 24, 2006 ©2006 Ethat potentiate the antimicrobial 
function of macrophages through 
release of interferon-γ (IFN-γ). There 
is extensive genetic and functional 
evidence that the Th1 response is 
essential for resistance to myco-
bacterial infection in humans and 
in animal models. Indeed, induction 
of IFN-γ-positive T cells is a central 
theme in the search for new vac-
cines. A common approach is to 
select antigens that are prominent 
targets of the immune response to 
natural infection. This includes a 
diverse repertoire, with a few favor-
ite proteins selected as a result of 
repeated identification in multiple 
experimental systems. The “antigen 
85 complex” is a family of proteins 
secreted in large amounts into the 
growth medium of M. tuberculosis 
cultures; antigens 85A and 85B have 
both been used in vaccines. ESAT6 
is another prominent target found in 
culture filtrates. It is released from 
the bacteria by a specialized secre-
tion system and forms a complex 
with a partner protein, CFP10. The 
genes encoding ESAT6 and CFP10 
were deleted during attenuation of 
BCG, and these antigens have an 
important diagnostic role in distin-
guishing BCG vaccination from M. 
tuberculosis infection (e.g., Soysal 
et al., 2005). This diagnostic appli-
cation argues against use of ESAT6 
in vaccines, but further members 
of the same low-molecular-weight 
protein family are conserved in BCG 
and offer alternative candidates. 
Although the biological function of 
the ESAT6 family is unknown, there 
is evidence that their unusual mode 
of secretion may play some role in 
immunogenicity (Pym et al., 2003). 
Proteins present inside the bacte-
ria are also effective in vaccines: 
Mtb72f, for example, is a fusion 
protein derived from two cytoplas-
mic proteins (Skeiky et al., 2004). 
To induce a Th1 immune response, 
these antigens have been delivered 
as purified proteins in adjuvant, as 
components of recombinant viral or 
bacterial vaccine vectors, or in the 
form of DNA vaccines. Hundreds of 
formulations have been screened in 
experimental animal models (Orme, lsevier Inc.2006); those going forward to clini-
cal trials have shown efficacy at 
least comparable to BCG.
Experience with BCG illustrates 
fundamental problems inherent in 
predicting the clinical impact of TB 
vaccines by extrapolation from their 
efficacy in animal models. New vac-
cines must be assessed for immu-
nogenicity and ultimately protec-
tive efficacy in human trials. Four 
new Th1 vaccines entered phase I 
trials by the end of 2005: MVA85A 
(the antigen 85A gene delivered in 
recombinant vaccinia virus Ankara), 
Mtb72f fusion protein delivered in 
AS02 adjuvant, rBCG30 (a recom-
binant BCG overexpressing antigen 
85B), and an ESAT6-85B fusion 
protein delivered in IC31 adjuvant. 
All of the vaccines will undergo 
extensive safety analysis in individ-
uals lacking prior antimycobacterial 
immunity, in individuals with evi-
dence of previous infection, and in 
individuals infected with HIV. Test-
ing of MVA85A is most advanced, 
with trials in the United Kingdom 
and the Gambia showing evidence 
of strong IFN-γ responses following 
BCG vaccination and an MVA85A 
boost (McShane et al., 2004).
Alternative Vaccine Strategies
Although Th1 boosting is the most 
obvious approach to TB vaccine 
development, it is important to con-
sider alternative vaccine strategies. 
TB often occurs as a secondary 
disease in individuals who had been 
able to control a primary infection; 
this is the reverse of the simple vac-
cine model based on the premise 
that prior exposure enhances sub-
sequent protection. BCG vaccina-
tion and M. tuberculosis infection 
already induce Th1 responses to 
the prominent antigens, and it is not 
clear that more IFN-γ will necessar-
ily translate into better protection. 
Given that the same Th1 response 
contributes to the pathology associ-
ated with clinical TB, it is conceiv-
able that vaccination could in fact 
exacerbate subsequent disease. 
This was the outcome of Robert 
Koch’s ill-fated exploration of ther-
apeutic vaccination for TB in the 
1890s and is reflected in adverse 
effects that can result from recon-
stitution of immune responses fol-
lowing antiretroviral treatment of 
patients coinfected with HIV and M. 
tuberculosis.
In addition to CD4+ T cells, multiple 
immune mechanisms are induced in 
response to mycobacterial infection 
and represent potential targets for 
vaccination. CD8+ T cells are required 
for optimal protection in mice, and 
recombinant adenovirus vectors pro-
vide an attractive strategy for induc-
tion of human CD8+ T cell responses 
to specific mycobacterial antigens. A recombinant BCG strain (rBCG∆Ure-
Hly) has been engineered to elicit a 
broad repertoire of CD8+ T cells by 
delivery of antigens into the cytoplasm 
of infected cells or by crosspriming of 
other antigen-presenting cells and is 
scheduled to enter clinical trials this 
year (Kaufmann, 2005). Although 
their functional contribution to pro-
tection and patterns of priming and 
recall are as yet poorly understood, 
CD1-restricted T cells capable of rec-
ognizing mycobacterial lipid antigens, 
and T cells expressing a γδ recep-
tor, provide future scope for immune 
modulation.Cell 124, FebFigure 1. The Potential Impact of 
 Different Kinds of Vaccines on the 
Incidence of Tuberculosis
The figure shows the impact of four strate-
gies that use vaccines alone (A) or in combi-
nation with drug treatment (B). Calculations 
have been carried out with an age-structured 
mathematical model (Dye et al., 1998) set up 
to investigate the effect of vaccination on a TB 
epidemic like that in south Asia with an annual 
incidence set at about 200 per 100,000 popu-
lation in 2015. Mass vaccination of uninfected 
populations (that is, pre-exposure) would re-
duce the annual incidence to 20 per 100,000 
in 2050. In a country the size of India, this 
would correspond to prevention of 50 million 
cases. A dual-action vaccine active both pre- 
and postexposure would prevent a further 5 
million cases, reducing the incidence to 14 
per 100,000. Implementation of effective drug 
treatment on its own would reduce the an-
nual incidence to 25 per 100,000 by 2050 (B). 
Combining drug treatment and vaccination 
would reduce incidence to 8 per 100,000 in 
a single campaign and 6 per 100,000 through 
repeated mass vaccination.Cytokine pathways outside of the 
major Th1 axis may be important in 
the balance between protective and 
pathological effects of immune acti-
vation. Th2 responses resembling 
those associated with allergy and 
worm infection are thought to exac-
erbate immunopathology during 
progressive TB and may also influ-
ence disease susceptibility. These 
responses may be open to manipu-
lation by Th2-suppressing vaccine 
strategies (Rook et al., 2005).
The 10% “failure” rate of the natu-
ral immune response is clearly suf-
ficient to support the lifestyle of M. 
tuberculosis and may represent the 
outcome favored by the pathogen. 
Indications that M. tuberculosis can 
contribute to programming of the 
host immune response are emerging 
from molecular epidemiology stud-
ies. For example, members of the 
“Beijing” family of M. tuberculosis 
suppress innate immune responses 
by expressing a phenolic glycolipid 
molecule (Reed et al., 2004). Also, 
fine tuning of pathogenic interac-
tions by mutations affecting expres-
sion of immune modulators provides 
one possible explanation for the 
observed association of particular 
phylogenetic branches of M. tuber-
culosis with particular human eth-
nic groups (Hirsh et al., 2004). If M. ruary 24, 2006 ©2006 Elsevier Inc. 685
tuberculosis has evolved a comfort-
able symbiosis with natural immu-
nity, perhaps vaccines should aim 
to change this balance rather than 
to enhance the status quo.
The Target and Impact of 
Vaccination
The simplest application of a new TB 
vaccine would involve delivery in tan-
dem with neonatal BCG. Anticipated 
outcomes would be an enhancement 
of BCG protection against childhood 
TB and, crucially, a reduction in sub-
sequent rates of infectious pulmo-
nary TB. However, since the peak 
onset of pulmonary disease in high-
burden countries is among young-
adult age groups, there will be a pro-
longed delay between administration 
of a new vaccine and measurement 
of its key impact. Direct vaccina-
tion of high-risk age groups would 
accelerate the impact of vaccination 
but has to address the fact that the 
majority of young adults have already 
been infected with M. tuberculosis. 
The requirements for a vaccine that 
augments a preexisting immune 
response are not well understood. It 
may be that boosting of the response 
during latent infection will be analo-
gous to boosting of prior BCG vacci-
nation and that the same vaccine will 
have a dual application for pre- and 
postexposure delivery. Alternatively, 
it can be envisaged that the immune 
response involved in containment of 
latent infection will comprise a tightly 
constrained network of effector and 
regulatory T cells. A postexposure 
vaccine would then have to operate 
by inducing responses outside of the 
established immune repertoire, for 
example, by targeting antigens pref-
erentially expressed by the form of 
M. tuberculosis that persists during 
latent infection.
We can explore the potential 
impact of these different kinds of 
vaccines and different vaccina-
tion strategies using mathematical 
modeling (Dye et al., 1998). Figure 
1 illustrates the potential impact 
of vaccines in an area of the world 
where TB is highly endemic but in 
slow decline—in this case, south 
Asia (WHO, 2006). This general 686 Cell 124, February 24, 2006 ©2006 Epattern is typical of Asia, the Middle 
East, and Latin America. For illustra-
tion, we suppose that the incidence 
rate is around 200 per 100,000 pop-
ulation in 2010, falling at 1%–2% 
per year (Figure 1, black line). The 
model can then be used to explore 
the potential effects of different 
kinds of vaccine, assuming that all 
would be available for use in 2015 
and that the combination of popu-
lation coverage and efficacy would 
protect 70% of the target popula-
tion from developing infectious or 
noninfectious forms of TB.
If a pre-exposure vaccine were 
used to protect infants only, the 
impact on the TB epidemic would 
become significant after a delay of 
10–15 years (Figure 1A, red line). 
Incidence could be reduced much 
sooner in a mass vaccination cam-
paign targeted at uninfected people 
of all ages. One round of vaccination 
in 2015 (in addition to routine neona-
tal vaccination) would cause a sharp 
reduction in incidence within about 
5 years (Figure 1A, green line). The 
decline would continue slowly there-
after, aided by the continuing effect 
of vaccinating infants.
A vaccine with dual action, which 
protects infected (postexposure) as 
well as uninfected (pre-exposure) 
people from developing active TB, 
would of course have greater impact. 
But the extra effect is likely to be 
modest between 2015 and 2050 
(Figures 1A and 1B, purple line). 
The additional benefits of protection 
postexposure are relatively small 
because, in an area of moderate 
transmission, the annual incidence of 
TB among infected people is smaller 
than among previously uninfected 
people. There are therefore fewer 
cases to be prevented. This compar-
atively small effect is also visible for 
a single-action vaccine that protects 
postexposure but not pre-exposure 
(Figure 1A, blue line).
This is not to say that protection 
postexposure is any less desirable. 
Protecting infected people from pro-
gressing to active TB is going to be 
crucial during the endgame of TB con-
trol. As transmission and incidence 
are reduced, a growing proportion of lsevier Inc.patients arises from the reactivation 
of latent infections, acquired when 
the transmission rate was still high. 
Eventually, such patients will be in 
the majority. The only way to prevent 
TB arising from reactivation is with a 
postexposure vaccine or by preven-
tive drug therapy.
Although it is possible that 
researchers will discover a “block-
buster” vaccine that can transform 
global TB on its own, a more realis-
tic scenario is that a partially effec-
tive vaccine will work together with 
new drugs. Figure 1B illustrates 
the impact of a drug treatment 
program, introduced from 2015 
onward, meeting the WHO targets 
of treating 70% of the new cases 
arising each year and curing 85% of 
them (Figure 1B, red line). A dual-
action vaccine, also introduced in 
2015, would supplement the effect 
of drug treatment (Figure 1B, green 
line), but the additional impact of 
the vaccine is less than would be 
obtained by vaccination alone. 
Drug treatment and vaccination are 
substitutive rather than synergistic 
because they partly serve the same 
function. Drugs prevent the trans-
mission of infection from patients 
(as well as curing them), whereas 
vaccines prevent the acquisition 
of infection by unexposed people. 
Periodic mass vaccination cam-
paigns with the dual-action vaccine 
could further push down incidence 
(Figure 1B, dark red line).
Although a new vaccine would 
undoubtedly be used worldwide, its 
efficacy (like that of BCG) might not 
be the same everywhere. In particu-
lar, it remains to be seen whether a 
TB vaccine can protect immuno-
compromised people who are HIV 
positive, whether they are vaccinated 
before or after exposure to one or 
both pathogens. 
In sum, the impact of vaccination is 
likely to be greater where drug treat-
ment programs have been less suc-
cessful. Although the prevention of 
infection is of the highest importance 
in areas of intense transmission, the 
protection of people who have already 
been infected will be vital during the 
elimination phase of TB control.
TB Vaccine Development Pipeline
The availability of an effective, 
licensed vaccine by the year 2015 
has been proposed as a realistic 
target within The Global Plan to 
Stop TB (Stop TB Partnership and 
WHO, 2006). To reach this goal, it 
is estimated that at least 20 vac-
cine candidates should enter phase 
I safety trials, with around half going 
forward for immunological evalua-
tion in phase II trials and leading to 
four phase III efficacy trials. Based 
on the number and cost of individu-
als enrolled in the trials, together 
with costs associated with vaccine 
production and trial-site develop-
ment, a budget in the region of $600 
million will be required to carry out 
this program.
Success in the clinical trials pro-
gram will depend on continued 
close integration with discovery 
research. Basic research input will 
be required to provide immunologi-
cal evidence to underpin the crucial 
decisions that have to be taken in 
selecting candidates for progres-
sion from immunogenicity studies to 
expensive efficacy trials; optimizing 
the chances of success will depend 
on interpretation of phase II data in 
the context of a broad understand-
ing of fundamental immunology 
and parallel findings in experimen-
tal models. It will also be important 
to continue to develop new can-
didates, using the data emerging 
from clinical trials to inform increas-
ingly rational design in an iterative 
learning process. Extrapolating 
from the current level of support for 
TB vaccine-related research, it is 
estimated that a sustained level of 
funding of around $120 million per 
year will be required.Taken together, the research, 
clinical trial, and production 
requirements for a new TB vaccine 
by the year 2015 amount to 1.8 bil-
lion dollars. The costs for main-
taining global BCG vaccination 
amount to 1.3 billion dollars over 
the same period. This represents 
a formidable multidisciplinary pro-
gram requiring collaboration of 
scientists in academia and indus-
try, clinicians and public-health 
professionals, and communities 
participating in trials. TB vaccine 
development has been fostered 
by important large-scale initia-
tives including the standardization 
of reagents and preclinical testing 
funded by the National Institutes 
of Health and the support for col-
laborative research consortia by 
the European Commission. Fund-
ing from the Bill & Melinda Gates 
Foundation supports the Aeras 
Global TB Vaccine Foundation, 
which interacts with academic and 
industrial partners in a dynamic 
program to accelerate clinical tri-
als of new TB vaccines. Aeras uses 
processes that parallel those of a 
commercial vaccine manufacturer, 
but within a global access frame-
work designed to deliver products 
at affordable costs in high-burden 
countries. As part of a recent initia-
tive to address “Grand Challenges 
in Global Health,” the Bill & Melinda 
Gates Foundation also funds two 
new research consortia focused 
on development of vaccines for 
latent TB and identification of bio-
markers for use in TB clinical trials. 
These initiatives and more will play 
an essential role in making good 
on the promise of vaccination for 
control of global TB.Cell 124, FebReFeRences
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